DOCSLIB.ORG

Account No Customer Email Country 1 41760 1001 ORGANIC LTD (TWIGA BREWERY) [email protected] TANZANIA A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Account No Customer Email Country 1 41760 1001 ORGANIC LTD (TWIGA BREWERY) Info@Twigabrew.Co.Tz TANZANIA A SN Account No Customer Email Country 1 41760 1001 ORGANIC LTD (TWIGA BREWERY) [email protected] TANZANIA A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE 2 6513 S.R.L [email protected] ITALY 3 80625 AA PHARMACEUTICALS LTD [email protected] TANZANIA 4 9964 ABACUS CHEMISTS LTD [email protected] TANZANIA 5 6852 ABACUS PARENTERAL DRUGS LIMITED [email protected] UGANDA 6 8473 ABACUS PHARMA AFRICA LIMITED [email protected] TANZANIA 7 4919 ABBOTT LABORATORIES S.A (PTY) LTD. [email protected] SOUTH AFRICA 8 3341 ABBOTT PRODUCTIONS SAS [email protected] FRANCE 9 5229 ABBVIE (PTY) LIMITED [email protected] SOUTH AFRICA 10 16622 ABIC BIOLOGICAL LABORATORIES ISRAEL 11 36314 ABIL CHEMPHARMA PVT LTD [email protected] INDIA 12 96445 ABNER PHARMACEUTICALS LIMITED [email protected] TANZANIA 13 5905 ABRAHAM SIFUELI KOWERO [email protected] TANZANIA 14 15382 ACCORD HEALTHCARE LIMITED. [email protected] INDIA 15 34226 ACE LABORATORIES LIMITED. [email protected] INDIA 16 28233 ACINO AG [email protected] GERMANY 17 3885 ACINO PHARMA AG [email protected] SWITZERLAND 18 69168 ACL CLEANER AND HYGIENE [email protected] TANZANIA 19 94436 ACME DIET CARE PVT LTD [email protected] INDIA 20 40751 ACME FORMULATION PRIVATE LIMITED [email protected] INDIA 21 62794 ACME LABORATORIES LIMITED [email protected] Bangladesh 22 95809 ACME LIFE TECH LLP [email protected] INDIA ACTION MEDEOR GERMAN MEDICAL AID 23 50673 ORGANISATION [email protected] GERMANY 24 6535 ACTION MEDEOR INTERNATIONAL HEALTHCARE [email protected] TANZANIA 25 50385 ACTIVA PHARMACEUTICALS FREE ZONE COMPANY [email protected] U.A.E 26 3593 ACULIFE HEALTHCARE PRIVATE LIMITED [email protected] INDIA 27 99101 ADAVANON PHARMA PVT LTD [email protected] INDIA 28 6664 ADCOCK INGRAM HEALTH CARE EXPORT DIVISION [email protected] SOUTH AFRICA 29 16717 ADCOCK INGRAM HEALTHCARE PRIVATE LIMITED [email protected] INDIA 30 68332 ADCOCK INGRAM LIMITED [email protected] SOUTH AFRICA ADVANCED AGROCHEMICALS AND VETERINARY 31 19800 PRODUCTS INDUSTRIAL CO (CHEMVET) [email protected] JORDAN 32 55669 ADVANCED PHARMACEUTICALS CO. LIMITED [email protected] JORDAN 33 82529 ADVANOV PHARMA PVT. LTD [email protected] INDIA 34 75770 ADVANTAGE RESEARCH LABORATORIES INC [email protected] USA 35 64904 ADWIA PHARMACEUTICALS S.A.E [email protected] EGYPT 36 59631 AEGIS LIMITED [email protected] CYPRUS 37 52700 AETHER CENTRE (BEIJING) BIOLOGY CO., LTD. CHINA 38 47808 AFRICURE PHARMACEUTICAL TANZANIA LTD [email protected] TANZANIA 39 7043 AFRIMAQ DISTRIBUTORS LIMITED [email protected] TANZANIA 40 23815 AFYA LABORATORIES LIMITED. [email protected] TANZANIA 41 27976 AGILA SPECIALTIES PRIVATE LIMITED [email protected] INDIA 42 92680 AGIO PHARMACEUTICALS LIMITED [email protected] INDIA 43 11295 AGLOWMED LIMITED [email protected] INDIA 44 7904 AGOG PHARMA LTD [email protected] INDIA 45 55218 AGRAR HOLLAND BV [email protected] NETHERLANDS 46 6595 AIRTEL TANZANIA LIMITED [email protected] TANZANIA 47 3799 AJANTA PHARMA LIMITED [email protected] INDIA 48 8045 AKACIA HEALTHCARE (PTY) LTD [email protected] SOUTH AFRICA 49 16455 AKRITI PHARMACEUTICALS PVT LTD [email protected] INDIA 50 54387 AKROMED PRODUCTS (PTY) LIMITED. [email protected] SOUTH AFRICA 51 33209 ALBERT DAVID LIMITED. [email protected] INDIA 52 9720 ALCON-COUVREUR NV [email protected] SOUTH AFRICA 53 70375 ALEMBIC PHARMACEUTICALS LIMITED [email protected] INDIA ALEXANDRIA CO. FOR PHARMACEUTICALS & 54 38463 CHEMICAL INDUSTRIES [email protected] EGYPT 55 5510 ALFASAN INTERNATIONAL B.V [email protected] Holland 56 18438 ALFEREZ PVT LIMITED. [email protected] INDIA 57 1124920 ALKA GENERAL ENTEPRISESS [email protected] TANZANIA 58 79955 ALKEM LABORATORIES LIMITED [email protected] INDIA 59 18959 ALLERGAN PHARMACEUTICALS (PTY) LIMITED. [email protected] SOUTH AFRICA 60 62108 ALPHACEUTICALS LIMITED [email protected] UNITED KINGDOM 61 49790 ALPHARMA LIMITED. [email protected] UNITED KINGDOM 62 73170 ALSTON GARRARD & CO LTD [email protected] UK 63 33546 AMANTA HEALTHCARE LIMITED [email protected] INDIA 64 72445 AMBALAL SARABHAI ENTERPRISES LIMITED [email protected] INDIA 65 11596 AMBONI SISAL PROPERTIES LIMITED [email protected] TANZANIA 66 50984 AMIN IMPEX PVT LTD [email protected] INDIA 67 91759 AMKA PRODUCTS (PTY) LIMITED [email protected] SOUTH AFRICA 68 9182 AMMAN PHARMACEUTICAL INDUSTRIES COMPANY [email protected] JORDAN AMOUN PHARMACEUTICAL INDUSTRIES COMPANY S. 69 1973 A. E [email protected] EGYPT 70 9521 AMRING FARMA S.R.L [email protected] Romania 71 46472 AMRIYA PHARMACEUTICAL INDUSTRY COMPANY [email protected] EGYPT 72 82420 ANFARM HELLAS S.A [email protected] GREECE 73 59527 ANGLO- FRENCH GRUGS & INDUSTRIES LIMITED [email protected] INDIA 74 2334 ANICROP SERVICES LTD [email protected] TANZANIA 75 1111 ANIMAL CARE COMPANY LTD [email protected] TANZANIA 76 9221 ANUPCO LIMITED [email protected] ENGLAND 77 77282 ARBRO PHARMACEUTICALS LIMITED [email protected] INDIA 78 54331 ARENCO PHARMACEUTICA N.V [email protected] BELGIUM 79 72489 ARISTO PHARMACEUTICALS PRIVATE LIMITED [email protected] INDIA 80 4632 ARTEMIS LIFE SCIENCES [email protected] U.A.E 81 61644 ARTEPHARM CO. LTD. [email protected] CHINA 82 25915 ARTISAN BAKERY INDIA 83 4333 ARUSHA TECHNICAL COLLEGE [email protected] TANZANIA 84 1563 ARYA LIMITED [email protected] TANZANIA 85 42411 ASHISH LIFE SCIENCE PVT LIMITED [email protected] INDIA 86 72491 ASIA ANIMAL PHARMACEUTICAL CO.,LTD [email protected] VIETNAM 87 80613 ASPEN PHARMACARE LIMITED [email protected] SOUTH AFRICA 88 64435 ASPIRO PHARMA LIMITED [email protected] INDIA 89 7272 ASSIA PHARMACEUTICALS LIMITED [email protected] KENYA 90 97592 ASTELLAS PHARMA TANZANIA 91 44782 ASTELLAS PHARMA( PTY) LIMITED [email protected] SOUTH AFRICA 92 44384 ASTRA LIFECARE INDIA LTD. [email protected] INDIA 93 21835 ASTRAL PHARMACEUTICAL INDUSTRIES INDIA 94 9842 ASTRAZENECA UNITED KINGDOM LIMITED [email protected] UNITED KINGDOM 95 47975 ATAROST ALLG. TIERARZNEIMITTEL FABRICK GERMANY 96 4986 ATCO LABORATORIES PRIVATE LIMITED [email protected] PAKISTAN 97 9452 ATLAS PHARMACY LIMITED [email protected] TANZANIA 98 87878 ATRA PHARMACEUTICALS LIMITED INDIA 99 5226 ATSOKO TANZANIA LIMITED [email protected] TANZANIA 100 11579 AUREATE GROUP LIMITED [email protected] TANZANIA 101 84494 AUROBINDO PHARMA LIMITED [email protected] INDIA 102 22537 AUROCHEM LABORATORIES INDIA PRIVATE LIMITED [email protected] INDIA 103 51795 AUROLAB [email protected] INDIA 104 58762 AURONEXT PHARMA PRIVATE LIMITED [email protected] INDIA 105 27729 AVIAZURE LIMITED. KENYA 106 21106 AVICHEM (PTY) LTD [email protected] SOUTH AFRICA 107 39485 AWAMEDICA COMPANY [email protected] Iraq 108 65313 AXA PARENTERALS LIMITED [email protected] INDIA 109 53536 AYASOFYA EXPORT & IMPORT COMPANY LTD [email protected] TANZANIA 110 16971 AYRITH LIFECARE PVT. LTD [email protected] INDIA 111 29700 AZMA INDUSTRY TANZANIA 112 42007 AZTEC PHARMA PVT LTD INDIA 113 35317 B&O PHARM [email protected] FRANCE 114 46732 B.BRAUN HOSPITAL CARE GERMANY 115 47492 B.BRAUN PHARMACEUTICALS EPZ LTD [email protected] KENYA 116 41251 BACFO PHARMACEUTICALS INDIA 117 4842 BAFNA PHARMACEUTICALS PVT LTD [email protected] INDIA 118 3482 BAHARI PHARMACY [email protected] TANZANIA 119 4611 BAJUTA INTERNATIONAL (T) LTD. [email protected] TANZANIA 120 6906 BAL PHARMA LIMITED [email protected] INDIA 121 80512 BARAKAT PHARMACEUTICAL INDUSTRIES SYRIA 122 34607 BARCELONA ENTERPRISES LTD TANZANIA 123 26231 BARIKI PHARMACY LIMITED [email protected] TANZANIA UNITED STATES OF 124 22891 BATH & BODY WORKS AMERICA. 125 86603 BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED [email protected] INDIA 126 12020 BAXTER S.L SPAIN 127 2763 BAYER EAST AFRICA LIMITED [email protected] KENYA 128 23891 BAYER PROPRIETARY LIMITED SOUTH AFRICA 129 5243 BAYER SCHERING PHARMA AG [email protected] GERMANY 130 91663 BDA HEALTHCARE PVT LIMITED [email protected] INDIA 131 23565 BEIJING HOLLEY COTEC PHARMACEUTICALS CO., LTD [email protected] CHINA 132 94308 BEIT JALA PHARMACEUTICAL CO. LIMITED [email protected] Palestine 133 22613 BELTAPHARM SPA ITALY 134 88121 BERLIN-CHEMIE AG GERMANY 135 15184 BERNARD NJAU [email protected] 136 40130 BESINS HEALTHCARE SA [email protected] BELGIUM UNITED ARAB 137 36766 BEST AGENCY (T) LIMITED [email protected] EMIRATES 138 1868 BETA DRUGS LIMITED [email protected] INDIA 139 89650 BETA DRUGS PVT. LTD., [email protected] INDIA 140 1697 BETA HEALTHCARE INTERNATIONAL LIMITED [email protected] KENYA 141 80066 BETA PHARMACEUTICALS LIMITED [email protected] UNITED KINGDOM 142 19192 BEXIMCO PHARMACEUTICALS LTD. [email protected] Bangladesh 143 17655 BHARAT BIOTECH INTERNATIONAL LIMITED [email protected] INDIA 144 2137 BHARAT SERUMS AND VACCINES LIMITED [email protected] INDIA 145 82285 BHARGAVA PYTOLAB PVT. LTD INDIA 146 2041 BIDCO AFRICA LIMITED [email protected] TANZANIA 147 32978 BIEFFE MEDITAL S.A SPAIN 148 85351 BILHAM INTERNATIONAL CO. LTD [email protected] TANZANIA 149 67082 BILIM ILAC SANAYI VE TICARET ANONIM SIRKETI [email protected] TURKEY 150
Load more

Recommended publications
  • Global Competitiveness in Pharmaceuticals
    Ref. Ares(2014)77485 - 15/01/2014 GLOBAL COMPETITIVENESS IN PHARMACEUTICALS A EUROPEAN PERSPECTIVE* * § ¨ ALFONSO GAMBARDELLA , LUIGI ORSENIGO , FABIO PAMMOLLI November 2000 Report prepared for the Enterprise Directorate-General of the European Commission * The authors wish to thank G. Baio, N. Lacetera, L. Magazzini, M. Mariani, R. Pammolli, and M. Riccaboni for skillfull research assistance. * Sant’Anna School of Advanced Studies, Pisa, [email protected]. § Bocconi University, Milan, [email protected]. ¨ Faculty of Economics Richard M. Goodwin, University of Siena, [email protected]. Enterprise Papers Enterprise Papers are a mix of policy papers, sector-specific studies, and a combination of both. Written by the staff of the Enterprise Directorate-General, or by experts working in association with them, they aim to raise awareness of enterprise policy issues and stimulate debate. These papers do not necessarily reflect the opinion or position of the European Commission. Occasional ‘special editions’ may carry communications, conference proceedings, and reports to the Council. This report was prepared for the Enterprise Directorate-General by Alfonso Gambardella, Luigi Orsenigo and Fabio Pammolli. For further information, contact European Commission Enterprise Directorate-General Information and communication unit Rue de la Loi/ Wetstraat 200 B-1049 Brussels Fax: (32-2) 299 1926 To request copies, fax (32-2) 296 9930. E-mail: [email protected] A great deal of additional information on the European Union is available on the internet. It can be accessed through the Europa server (http://europa.eu.int). Luxembourg: Office for Official Publications of the European Communities, 2001 ISBN 92-894-1071-X © European Communities, 2001 Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • “Analysis of SCM: a Case Study of Wyeth Pharmaceutical Company”
    “Analysis of SCM: A case study of Wyeth Pharmaceutical company” Submitted by: Shahzad Ali Rajpar Supervised by: Mr. Muhammad Amir Adam Program: MBA FALL 2010 National University of Computer & Emerging Science Management Science Department, Karachi, Campus Page | 1 Acknowledgments Thanks to Allah the All Merciful the all Benevolent for providing me the strength, courage, direction and skills to learn, acquire knowledge, and the ability to accept and meet challenges. Second I would like to thank all those people who have helped me in performing this research study, especially Mr. Aftab Amie Siddiqui manager planning and warehouse, Wyeth Pharmaceutical Limited Pakistan. I would like to express my sincere gratitude to my supervisor Mr. Mohammad Amir Adam for providing me his precious time, guidance, and instructions all along in order to materialize my content for the project report. I would also like to thank the FYP Coordinator Mr. Zaki Rashidi for his assistance and guidance for the research project. I am also thankful to my parents who accommodated me during those long hours of work in my project development and all the friends and colleagues who helped me out in my times of weakness and encouraged me. I am hopeful that the effort will be fruitful for the students to come in FAST after us. Once again, I am very thankful to all people who have been involved in this project report directly or indirectly. Page | 2 Table of Contents Acknowledgments ............................................................................................. 2 Table of Contents .............................................................................................. 3 CHAPTER 1 “INTRODUCTION” ........................................................................... 6 1.1 Supply chain management. ..................................................................... 6 1.2 Evolution of supply chain management.
    [Show full text]
  • PHARMACEUTICAL September 2009
    PHARMACEUTICALS September 2009 PHARMACEUTICAL September 2009 The focus of this presentation is to discuss… Market overview Policy Key trends and drivers Key players Key opportunities 2 MARKET OVERVIEW Pharmaceutical September 2009 Indian pharmaceutical market — US$ 7.3 billion opportunity • India is among the fastest growing pharmaceutical markets in the world. • The pharmaceutical market was worth US$ 16.6 billion in 2007–08; the domestic retail market is expected to cross the US$ 10 billion mark in 2010 and reach an estimated US$ 12 billion to US$ 13 billion by 2012. Domestic pharma retail market Break up of Indian pharma industry 16 13.6 13.4 14 12 10.1 10 7.7 8 5.4 4.8 6 3.9 4.1 46% (US$ million) (US$ 4 2.5 2.6 54% 1.4 2 1.1 0 2002-03 2005-06 2007-08E 2012-13P Domestic Formulation Consumption (DFC) Domestic Formulation Consumption (DFC) Total exports Formulation exports Bulk drug export Source: Pharmaceuticals: industry profile, Dec 2008, CRIS INFAC Source: Pharmaceuticals: industry profile, Dec 2008, CRIS INFAC 3 MARKET OVERVIEW Pharmaceutical September 2009 Indian pharmaceutical market — US$ 7.3 billion opportunity • The outsourcing opportunity is set to grow to Forecasted Indian pharmaceutical retail market in US$ bn US$ 53 billion in 2010 from US$ 26 billion in 2006. • Retail sales of pharmaceuticals were US$ 7.7 billion in 2007–08. • Domestic consumption accounted for nearly 46 per cent and exports for the remaining 54 per cent of total industry revenues. Source: Compiled from industry sources 4 MARKET OVERVIEW Pharmaceutical September 2009 Anti-infectives — largest therapeutic category • The anti-infectives segment was the highest contributor (18 per cent) to total domestic sales in 2007–08.
    [Show full text]
  • Directory of Recognised In-House R&D Units
    DIRECTORY OF RECOGNISED IN-HOUSE R&D UNITS 2011 DEPARTMENT OF SCIENTIFIC & INDUSTRIAL RESEARCH MINISTRY OF SCIENCE AND TECHNOLOGY NEW DELHI Sl.No Registration Name and Address of the Firm Location of R&D Unit Recognition Number Valid Upto 1 TU/IV-RD/3105 20 Microns Nano Minerals Limited 11, GIDC Estate, Waghodia, 31.03.2013 307-308, Arundeep Complexes.Race Dist. Vadodrara, Gujrat Course ,Vadodara-390007, Gujarat 2 TU/IV-RD/3351 A.J Organica Pvt. Ltd. Plot . No 8 Survey No. 288 31.03.2014 Plot . No 8Survey No. 288,Raisoni Raisoni Indsutrial Estate Mann Indsutrial Estate Mann Taluka Mulshi Taluka Mulshi Hinjewadi Phase IIPune- 411057 3 TU/IV-RD/3153 Aadhaar Seeds Pvt. Ltd. Raja Bollaram (Village), 31.03.2014 1-5-12/2/2, New Maruthi Nagar, Medchal (Mandal), R. R. Dist. Kothapet, Hyderabad – 500 035 (AP) 4 TU/IV-RD/2141 Aarti Drugs Ltd. (i) Plot No.198, MIDC Tarapur, 31.03.2014 D-109, Gr. Floor, Mahendra Indl. Vill. Pamtembhi, Tal. Palghar, EstateRoad No. 29, Sion (E)Mumbai - Dist. Thane (ii) G-60, MIDC, 400 022 Tarapur, Tal. Palghar, Dist. Thane 5 TU/IV-RD/2193 Aarti Industries Ltd. Plot No.801, 801/23, GIDC 31.03.2012 Udyog Kshetra, 2nd FloorMulund- Estate, Phase III, Vapi, Dist. Goregaon Link Road, Mulund Valsad, Gujarat (W)Mumbai-400080 6 TU/IV-RD/637 Abbott India Ltd. L-18, Verna Ind. Area, Verna, 31.03.2013 3-4, Corporate ParkSion-Trombay Salcette, Goa Road,Chembur,Mumbai- 400071 7 TU/IV-RD/3180 ABC Genomics (India) Pvt. Ltd.
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/519 (2006.01) A61K 31/53 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/551 7 (2006.0 1) A61P 17/00 (2006.0 1) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US201 1/061062 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 16 November 201 1 (16.1 1.201 1) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/414,334 16 November 2010 (16. 11.2010) US kind of regional protection available): ARIPO (BW, GH, 61/414,348 16 November 2010 (16.
    [Show full text]
  • REGISTER of SPONSORS (Tiers 2 & 5 and Sub Tiers Only)
    REGISTER OF SPONSORS (Tiers 2 & 5 and Sub Tiers Only) DATE: 09-January-2017 Register of Sponsors Licensed Under the Points-based System This is a list of organisations licensed to sponsor migrants under Tiers 2 & 5 of the Points-Based System. It shows the organisation's name (in alphabetical order), the sub tier(s) they are licensed for, and their rating against each sub tier. A sponsor may be licensed under more than one tier, and may have different ratings for each tier. No. of Sponsors on Register Licensed under Tiers 2 and 5: 29,794 Organisation Name Town/City County Tier & Rating Sub Tier ?What If! Ltd London Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) @ Home Accommodation Services Ltd London Tier 2 (A rating) Tier 2 General Tier 5 (A rating) Creative & Sporting ]performance s p a c e [ london london Tier 5 (A rating) Creative & Sporting 01 Telecom Limited Brighton Tier 2 (A rating) Tier 2 General 0-two Maintenance London Tier 2 (A rating) Tier 2 General 1 Stop Print Ltd Ilford Tier 2 (A rating) Tier 2 General 1 Tech LTD London Tier 2 (A rating) Tier 2 General 10 Europe Limited Edinburgh Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) 10 GROUP LTD T/A THE 10 GROUP LONDON Tier 2 (A rating) Tier 2 General 10 Minutes With Limited London Tier 2 (A rating) Tier 2 General Page 1 of 1952 Organisation Name Town/City County Tier & Rating Sub Tier 1000heads Ltd London Tier 2 (A rating) Tier 2 General 1000mercis LTD London Tier 2 (A rating) Tier 2 General 100Starlings Ltd
    [Show full text]
  • Drugs and Pharmaceuticals "D".Pdf
    Drugs and Pharmaceuticals “D” NDC Code Description Manufacturer Basic Category UM 63323-0127-10 DACARBAZINE PR 100MG 10VL APP-AMER PHARM PTNRS CT Injectables/RX Drugs 63323-0128-20 DACARBAZINE PR 200MG 10VL APP-AMER PHARM PTNRS CT Injectables/RX Drugs 58768-0727-15 DACRIOSE 15ML NVR DR NOVARTIS OPHTHALMICS EA OTC 58768-0727-20 DACRIOSE DR 120ML NOVARTIS OPHTHALMICS EA OTC 10135-0115-01 DAILY MULTIPLE VIT RED 100 MARLEX PHARMACEUTICALS EA OTC 63739-0274-01 DAILY MULTI/IRON 750UD INST SKY PHARMACEUTICALS BX OTC 63739-0068-01 DAILY MULTIVITAMIN 750UD SKY PHARMACEUTICALS EA OTC INST 63739-0274-03 DAILY MULTIVTMN/IRON 25x30 SKY PHARMACEUTICALS BX OTC UDPC 00536-0410-59 DAILY VIT HOMOGEN 8oz SR WATSON LABS EA OTC 00536-3546-10 DAILY VIT IRON 1000 WAT TB WATSON LABS EA OTC 00536-3546-01 DAILY-VIT/IRON 100 WAT WATSON LABS EA OTC 00436-0946-16 DAKINS FS 0.5% 480ML NR SL CENTURY PHARMACEUTICALS EA OTC 50383-0624-16 DALYVITE 16oz SL HI-TECH PHARMACAL EA OTC COMPANY 49938-0101-01 DAPSONE 100MG 100 TB JACOBUS PHARMACEUTICAL EA Injectables/RX Drugs CO. INC 49938-0102-01 DAPSONE 25MG 100 TB JACOBUS PHARMACEUTICAL EA Injectables/RX Drugs CO. INC 00173-0201-55 DARAPRIM 25MG 100 GLX TB GLAXOSMITHKLINE EA Injectables/RX Drugs 00002-0363-02 DARVOCENT-N 100 TB 100 C4 TB A. A. I PHARMACEUTICALS EA Drug, DEA Schedule 00002-0363-33 DARVOCENT-N 100 TB 100UD C4 A. A. I PHARMACEUTICALS EA Drug, DEA Schedule TB 00002-0803-02 DARVON CP 65MG 100 C4 CP A.
    [Show full text]
  • Redacted Craig Mccann Opioid MDL ARCOS Report.Pdf
    Case: 1:17-md-02804-DAP Doc #: 1999-13 Filed: 07/25/19 1 of 154. PageID #: 264837 Confidential - Subject to Protective Order IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION IN RE NATIONAL : MDL No. 2804 PRESCRIPTION OPIATE : CASE NO. 17-MD-2804 LITIGATION : (DAP) : EXPERT REPORT OF CRAIG J. MCCANN, PH.D., CFA March 25, 2019 Case: 1:17-md-02804-DAP Doc #: 1999-13 Filed: 07/25/19 2 of 154. PageID #: 264838 Confidential - Subject to Protective Order Table of Contents I. Qualifications and Remuneration ..................................................... - 1 - A. Qualifications ......................................................................... - 1 - B. Remuneration ......................................................................... - 2 - II. Materials Reviewed .......................................................................... - 2 - III. Assignment ....................................................................................... - 4 - IV. Summary of Opinions ....................................................................... - 4 - V. ARCOS Data .................................................................................... - 7 - A. Receipt of ARCOS Data from the DEA ................................ - 7 - B. ARCOS Data Fields Produced by DEA ................................. - 9 - 1. Seller DEA Number .................................................................. - 11 - 2. Seller Business Activity ............................................................ - 12
    [Show full text]
  • Torreya In-Depth Study—The Future of the Global Pharmaceutical Industry
    The Future of the Global Pharmaceutical Industry October 2017 Ta b l e o f Co n te n t s Section Page 1. Executive Summary 3 2. Pharmaceutical Sector Has Grown Rapidly in the Last Century 7 - Widespread concerns about the sector today 8 - Thousandfold increase in value of companies in sector since 1920s 10 3. Pharmaceutical Sector Will Triple in Size in the Next 40 Years 12 - Pharmaceutical consumption econometrically close related to GDP growth 14 - Based upon expected GDP growth, the pharma sector will likely triple in size by 2060 19 4. Total Value of the Pharmaceutical Sector Today over $5 Trillion 20 - Total revenue in the pharma sector around $1.1 trillion in 2017 23 - Total value of companies in sector over $5 trillion. Pharma one of the world’s largest sectors 24 5. Pharma Will Be Positively Impacted by Growth in Rare Disease Drugs and China 27 - Cost controls widespread and likely to continue. Major impact on Europe market 28 - Rare disease pharma sector has grown in value by 1300% since 2000. To continue growing fast 37 - China to become a close #2 to the U.S. market in time. Dramatic growth to continue 49 6. Innovations in Inflammation Control, Nucleic Acids and Implantables Will Transform Industry 55 - Better Manufacture Will Facilitate Dramatic Growth in Peptide Therapeutics 56 - Control of Inflammation May Substantially Reduce Mortality from Cancer & Heart Disease 61 - Nucleic Acid Therapeutics a Source of Substantial Future Growth 65 - Cell Therapy is Becoming Mainstream in the Pharmaceutical Industry 70 - Implantables and Electroceuticals Will Redefine Therapeutic Sector 74 7.
    [Show full text]
  • Final Report Ventura County Medical Center 340B Drug Pricing Program
    Ventura County Grand Jury 2017 - 2018 Final Report Ventura County Medical Center 340B Drug Pricing Program April 26, 2018 This page intentionally blank Ventura County 2017 – 2018 Grand Jury Final Report Ventura County Medical Center 340B Drug Pricing Program Summary The 2017-2018 Ventura County Grand Jury (Grand Jury) opened an investigation after receiving a complaint about the Ventura County Medical Center’s (VCMC) 340B Drug Pricing Program (340B program). The 340B program requires pharmaceutical companies to provide prescription drugs at significant discounts to hospitals and clinics serving large numbers of low-income patients. In July 2015 an audit of VCMC was conducted by the federal Health Resources and Services Administration (HRSA). The audit discovered that VCMC received duplicate discounts on medications in the 340B program. A total of 107 pharmaceutical companies were affected by the duplicate discount billing. The total duplicate discounts were in excess of $3 million. The Grand Jury concluded there was inadequate oversight of the VCMC 340B program prior to the HRSA audit. This resulted in VCMC being required to reimburse pharmaceutical companies at least $861,000 and potentially as much as $1.6 million. The Grand Jury concluded while VCMC conducts its own in-house audits of the 340B program, more critical audits should be conducted by an independent outside party. The Grand Jury recommends VCMC consider bringing in outside resources with extensive 340B program experience to assist in the supervision of a corrective action plan. The Grand Jury also recommends VCMC request the Ventura County Auditor-Controller conduct regular compliance audits of the 340B program.
    [Show full text]
  • Global Competitiveness in Pharmaceuticals: a European Perspective
    Munich Personal RePEc Archive Global Competitiveness in Pharmaceuticals: A European Perspective Gambardella, Alfonso and Orsenigo, Luigi and Pammolli, Fabio IMT Institute For Advanced Studies, Lucca 1 November 2000 Online at https://mpra.ub.uni-muenchen.de/15965/ MPRA Paper No. 15965, posted 30 Jun 2009 09:08 UTC - GLOBAL COMPETITIVENESS IN PHARMACEUTICALS A EUROPEAN PERSPECTIVE* ∗ ♣ ♦ ALFONSO GAMBARDELLA , LUIGI ORSENIGO , FABIO PAMMOLLI November 2000 Report Prepared for the Directorate General Enterprise of the European Commission * The authors wish to thank G. Baio, N. Lacetera, L. Magazzini, M. Mariani, R. Pammolli, and M. Riccaboni for skillfull research assistance. ∗ Sant’Anna School of Advanced Studies, Pisa, [email protected]. ♣ Bocconi University, Milan, [email protected]. ♦ Faculty of Economics Richard M. Goodwin, University of Siena, [email protected]. I. INTRODUCTION............................................................................................... 2 II. STRUCTURAL INDICATORS IN THE EU, USA, AND JAPAN.................. 11 III. THE EUROPEAN AND US MULTINATIONALS: COMPARATIVE PERFORMANCE ...................................................................................................... 25 IV. R&D AND INNOVATION AS SOURCES OF COMPETITIVE ADVANTAGES.......................................................................................................... 36 IV.1 THE DIVISION OF INNOVATIVE LABOUR IN PHARMACEUTICALS ....................... 36 IV.2 THE US AS AN INCREASINGLY PREFERRED LOCATION FOR
    [Show full text]